JuliaKRotowMD

Oncology • Boston, MA

Physician

Join to view full profile

Dr. Rotow is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Rotow's full profile

Already have an account?

Office
450 Brookline Ave
Boston, MA 02215
Phone+1 617-632-5301

Fax+1 617-632-5786

Education & Training

Massachusetts General HospitalResidency, Internal Medicine, 2012 - 2015
David Geffen School of Medicine at UCLAClass of 2007

Certifications & Licensure

MA State Medical License 2019 - 2026
NH State Medical License 2024 - 2024
CA State Medical License 2015 - 2020
RI State Medical License 2020 - 2020
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

1 citations
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.
Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, Yu Qian, Xin Sun
Nature. 2024-11-01
7 citations
Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study.
Collin M Blakely, Anatoly Urisman, Matthew A Gubens, Claire K Mulvey, Greg M Allen
Journal of Clinical Oncology. 2024-09-10
2 citations
The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC.
Allison E B Chang, Andrew J Piper-Vallillo, Raymond H Mak, Michael Lanuti, Alona Muzikansky
The Oncologist. 2024-07-05

Journal Articles

Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient with a MET Exon 14 Skipping Mutation
Julia K Rotow, Trever G Bivona, Collin M Blakely, Clinical Lung Cancer

Authored Content

Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient with a MET Exon 14 Skipping MutationNovember 2018

Press Mentions

Brompton Grand Rounds: Multi-Modality Management in Early Lung Cancer—Target TreatmentsSeptember 16th, 2022
Podcast 300: NADIM II Trial Offers “Quite Exciting” Results in Lung CancerAugust 11th, 2022
Revisiting Chemo in EGFR-Mutant NSCLCDecember 3rd, 2019
Join now to see all